Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 898,096 shares, a growth of 187.6% from the June 15th total of 312,225 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 804,191 shares, the short-interest ratio is presently 1.1 days.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on the company. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. HC Wainwright dropped their price target on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rein Therapeutics in a research report on Friday, June 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.00.
View Our Latest Report on RNTX
Rein Therapeutics Price Performance
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. As a group, analysts expect that Rein Therapeutics will post -0.53 EPS for the current year.
Hedge Funds Weigh In On Rein Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in shares of Rein Therapeutics in the third quarter worth about $35,000. HRT Financial LP acquired a new stake in shares of Rein Therapeutics during the fourth quarter valued at approximately $38,000. Chicago Partners Investment Group LLC lifted its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after acquiring an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Rein Therapeutics in the 2nd quarter valued at approximately $68,000. Finally, Jane Street Group LLC acquired a new position in Rein Therapeutics in the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.
Rein Therapeutics Company Profile
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Rein Therapeutics
- Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger
- Alphabet’s AI Spending Question Looms Over Q2 Earnings
- 3 Small-Cap Stocks Trading Under $10 With Room to Run
- CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
